

Sandra Coral

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3021735/publications.pdf>

Version: 2024-02-01

40
papers

2,451
citations

257357

24
h-index

315616

38
g-index

48
all docs

48
docs citations

48
times ranked

3328
citing authors

#	ARTICLE	IF	CITATIONS
1	The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. <i>Molecular Oncology</i> , 2011, 5, 164-182.	2.1	281
2	Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2'-deoxycytidine. <i>Cancer Research</i> , 2004, 64, 9167-9171.	0.4	193
3	Endoglin: An accessory component of the TGF- β -binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. <i>Journal of Cellular Physiology</i> , 2001, 188, 1-7.	2.0	162
4	Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. <i>Cardiovascular Research</i> , 2010, 86, 12-19.	1.8	147
5	Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications. <i>Journal of Cellular Physiology</i> , 2007, 212, 330-344.	2.0	124
6	Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2'-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications. <i>Clinical Cancer Research</i> , 2007, 13, 3333-3338.	3.2	120
7	Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). <i>Journal of Immunotherapy</i> , 1999, 22, 16-24.	1.2	119
8	5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. <i>Clinical Cancer Research</i> , 2002, 8, 2690-5.	3.2	114
9	Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma. <i>Journal of Immunotherapy</i> , 2002, 25, 16-26.	1.2	111
10	Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. <i>Journal of Translational Medicine</i> , 2010, 8, 56.	1.8	94
11	Epigenetic drugs as immunomodulators for combination therapies in solid tumors. , 2014, 142, 339-350.		92
12	Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 4040-4047.	3.2	89
13	Epigenetic targets for immune intervention in human malignancies. <i>Oncogene</i> , 2003, 22, 6484-6488.	2.6	68
14	Analysis of Cancer/Testis Antigens in Sporadic Medullary Thyroid Carcinoma: Expression and Humoral Response to NY-ESO-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 748-754.	1.8	61
15	Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 605-614.	2.0	61
16	Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. <i>OncImmunology</i> , 2015, 4, e1019978.	2.1	61
17	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7351-7362.	3.2	61
18	Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2006, 207, 58-66.	2.0	52

#	ARTICLE	IF	CITATIONS
19	Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. <i>Journal of Translational Medicine</i> , 2011, 9, 78.	1.8	52
20	Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. <i>Journal of Translational Medicine</i> , 2012, 10, 185.	1.8	49
21	Epigenetic Modulation of Solid Tumors as a Novel Approach for Cancer Immunotherapy. <i>Seminars in Oncology</i> , 2005, 32, 473-478.	0.8	44
22	Methylation-regulated expression of HLA class I antigens in melanoma. <i>International Journal of Cancer</i> , 2003, 105, 430-431.	2.3	41
23	Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. <i>International Journal of Cancer</i> , 1995, 61, 548-556.	2.3	36
24	Epigenetics Meets Immune Checkpoints. <i>Seminars in Oncology</i> , 2015, 42, 506-513.	0.8	32
25	Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. <i>Journal of Cellular Physiology</i> , 2000, 185, 317-323.	2.0	26
26	5-AZA-2-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story. <i>Cancer Research</i> , 2007, 67, 2900-2900.	0.4	21
27	Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. <i>British Journal of Cancer</i> , 2012, 107, 1116-1124.	2.9	20
28	Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 1443.	1.6	20
29	Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. <i>Journal of Cellular Physiology</i> , 2010, 223, 352-358.	2.0	19
30	Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. <i>Cancers</i> , 2020, 12, 361.	1.7	19
31	Epigenetics of melanoma: implications for immune-based therapies. <i>Immunotherapy</i> , 2013, 5, 1103-1116.	1.0	18
32	Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN- γ . <i>International Journal of Cancer</i> , 2001, 91, 500-507.	2.3	10
33	In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 132-138.	2.0	8
34	Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells*. <i>Journal of Cellular Physiology</i> , 2002, 190, 200-206.	2.0	7
35	Epigenetic Markers of Prognosis in Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 481-499.	0.4	6
36	Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 487-488.	2.0	5

#	ARTICLE	IF	CITATIONS
37	Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy. <i>Epigenomes</i> , 2021, 5, 27.	0.8	3
38	Epigenetically regulated tumor-associated antigens in melanoma. <i>Expert Review of Dermatology</i> , 2009, 4, 145-154.	0.3	1
39	Unbalanced expression of HLAâ€A and â€B antigens: A specific feature of cutaneous melanoma and other nonâ€hemopoietic malignancies reverted by IFNâ€³. <i>International Journal of Cancer</i> , 2001, 91, 500-507.	2.3	1
40	â€œCancer Bio-Immunotherapy in Sienaâ€: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17â€19, 2013. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 131-135.	2.0	0